PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
7.93%
ROE 75-90% of AVXL's 10.01%. Bill Ackman would demand evidence of future operational improvements.
-692.49%
Both firms have negative ROA. Martin Whitman would investigate if the market environment is extremely challenging.
20.70%
Similar ROCE to AVXL's 19.79%. Walter Schloss would see if both firms share operational best practices.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.